MAJI (Exousia Pro) 9-Day RSI: 33.45 (As of Jul. 12, 2026)


What is Exousia Pro 9-Day RSI?

Exousia Pro MAJI -3.33% 9-Day RSI is 33.45 as of Jul. 12, 2026.

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

As of today (2026-07-12), Exousia Pro's 9-Day RSI is 33.45.

The industry rank for Exousia Pro's 9-Day RSI or its related term are showing as below:

MAJI's 9-Day RSI is not ranked
in the Biotechnology industry.
Industry Median: 50.12 vs MAJI: 33.45

Exousia Pro  (OTCPK:MAJI) 9-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.

Exousia Pro 9-Day RSI Related Terms

MAJI vs HCCH, GRNV, AGBA: 9-Day RSI Comparison

For the Biotechnology subindustry, Exousia Pro's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Exousia Pro 9-Day RSI vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exousia Pro's 9-Day RSI distribution charts can be found below:

* The bar in red indicates where Exousia Pro's 9-Day RSI falls into.


Exousia Pro  (OTCPK:MAJI) 9-Day RSI Calculation

The formula for calculating RSI is:

RSI=100–[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 9-Day RSI →
What does a 9-Day RSI of 33.45 mean?
Exousia Pro (MAJI) has a 9-Day RSI of 33.45 as of Jul. 12, 2026.
Is Exousia Pro's 9-Day RSI too high?
Exousia Pro's current 9-Day RSI is 33.45. The Biotechnology industry median 9-Day RSI is 50.12. Exousia Pro's value of 33.45 is 33.3% below this industry median.
How does Exousia Pro's 9-Day RSI compare to HCCH and GRNV?
Exousia Pro's 9-Day RSI of 33.45 can be compared against companies in the Biotechnology industry. The industry median 9-Day RSI is 50.12. Exousia Pro's value of 33.45 is 33.3% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Biotechnology company?
The median 9-Day RSI among Biotechnology companies is 50.12, based on 1,422 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Exousia Pro's current 9-Day RSI of 33.45 is 33.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median 9-Day RSI is 50.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Exousia Pro's current 9-Day RSI is 33.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exousia Pro stock overvalued right now?
Exousia Pro (MAJI) has a current 9-Day RSI of 33.45. The current 9-Day RSI is 33.45 and 33.3% below the Biotechnology industry median of 50.12. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Exousia Pro (MAJI), the current 9-Day RSI is 33.45 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Exousia Pro Business Description

Address 7901 4th Street North, No. 23494, St. Petersburg, FL, USA, 33702
Exousia Pro Inc is a exosome-based biotechnology, develops and manufactures mammalian and plant-based exosomes using proprietary technologies for nucleic acid loading and targeted delivery to tissues and cells. The company is developing new ways to exploit the therapeutic potential of exosomes, initially focused in the field of oncology. The platform technology of the company also helps treating a broad spectrum of viral infections.